Source: Annual Congress 2005 - Pulmonary thromboembolic disease
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Bonderman, R. Nowotny, N. Skoro-Sajer, C. Adlbrecht, J. Jakowitsch, I. M. Lang (Vienna, Austria). Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Eur Respir J 2005; 26: Suppl. 49, 1831

Member's Comments

No comment yet.

Related content which might interest you: Bosentan for inoperable chronic thromboembolic pulmonary hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 399s Year: 2006 Bosentan improves 6-minutes-walk-test in patients with inoperable chronic thrombo-embolic pulmonary hypertension (iCTEPH) Source: Eur Respir J 2005; 26: Suppl. 49, 272s Year: 2005 Pharmacological therapy for patients with chronic thromboembolic pulmonary hypertension Source: Eur Respir Rev 2015; 24: 272-282 Year: 2015 Initial dual oral combination therapy in inoperable chronic thromboembolic pulmonary hypertension (CTEPH) Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Successful use of sildenafil in the treatment of pulmonary hypertension in patients with severe non-operable chronic thromboembolic disease Source: Annual Congress 2004 - Treatment of pulmonary hypertension Year: 2004 The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study Source: Eur Respir J 2006; 28: 138-143 Year: 2006 Longterm survival of inoperable chronic thromboembolic pulmonary hypertension (CTEPH) Source: Annual Congress 2008 - Acute and chronic pulmonary thromboembolic disease Year: 2008 Vasodilator treatment in chronic thromboembolic pulmonary hypertension Source: Annual Congress 2003 - Update on chronic thromboembolic pulmonary hypertension Year: 2003 Sequential multimodal therapy in patients with chronic thromboembolic pulmonary hypertension (CTEPH) Source: Virtual Congress 2020 – Chronic thromboembolic pulmonary hypertension Year: 2020 Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension Source: Eur Respir J 2007; 30: 922-927 Year: 2007 Effects of sildenafil as a bridge therapy for pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Comparison of clinical characteristics in patients with pulmonary arterial hypertension and inoperable chronic thromboembolic pulmonary hypertension Source: Annual Congress 2008 - Pulmonary venous thromboembolic disease Year: 2008 Adherence to disease-specific drug treatment among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension Source: ERJ Open Res, 6 (4) 00299-2020; 10.1183/23120541.00299-2020 Year: 2020 Surgical and post-operative treatment of chronic thromboembolic pulmonary hypertension Source: Eur Respir Rev 2009; 19: 64-67 Year: 2010 Multi-step therapy with riociguat, balloon pulmonary angioplasty, and cardiac rehabilitation for inoperable chronic thromboembolic pulmonary hypertension Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension Year: 2017 Real-life data on the medical therapy of pulmonary arterial and chronic thromboembolic pulmonary hypertension Source: International Congress 2017 – PAH and CTEPH Year: 2017 Managing chronic thromboembolic pulmonary hypertension: pharmacological treatment options Source: Eur Respir Rev 2009; 18: 24-28 Year: 2009 Pulmonary endarterectomy: the potentially curative treatment for patients with chronic thromboembolic pulmonary hypertension Source: Eur Respir Rev 2015; 24: 263-271 Year: 2015 Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension Source: Eur Respir J 2004; 23: 595-600 Year: 2004 Diagnosis of chronic thromboembolic pulmonary hypertension Source: Eur Respir Rev 2017; 26: 160108 Year: 2017